Comparison of Different Radiation Techniques to Achieve Normal Tissue Sparing and Target Volume Coverage in the Treatment of Left-sided Early Stage Breast Cancer

2012 ◽  
Vol 84 (3) ◽  
pp. S244-S245
Author(s):  
M. Mislmani ◽  
C. Weller ◽  
S. Anthony ◽  
G. Severino ◽  
P. Silverman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Normal Tissue ◽  
Early Stage ◽  
Target Volume ◽  
Early Stage Breast Cancer ◽  
Normal Tissue Sparing ◽  
Tissue Sparing

Dosimetric evaluation and comparison of small-field non-coplanar multi-arc radiotherapy (SMART) and intensity-modulated radiotherapy (IMRT) in treatment of tumor-related bronchial/superior vena cava (SVC) obstructions

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 19668-19668
Author(s):  
A. T. Figura ◽  
J. Montebello ◽  
J. Wang ◽  
H. Zhang ◽  
N. Mayr ◽  
...  
Keyword(s):  
Cancer Progression ◽  
Normal Tissue ◽  
Vena Cava ◽  
Target Volume ◽  
Bronchial Obstruction ◽  
Treatment Delivery ◽  
Dose Volume Histograms ◽  
Normal Tissue Sparing ◽  
Total Body ◽  
Tissue Sparing

19668 Background: Rapid and cost-effective palliation is of great importance in patients with complications from lung cancer progression. To offer immediate treatment for a tumor-related obstructed bronchus or SVC, we have implemented the SMART technique which has been shown to be effective and safe in the primary and re-treatment of malignant bronchial/SVC obstructions. The purpose of this study was to determine if the dose coverage to the obstructed bronchus/SVC and normal tissue sparing achieved by SMART compare favorably to the lengthier and more expensive IMRT technique. Methods: Treatment planning CT’s from 9 patients with a bronchial obstruction and 1 with SVC were studied. The planning target volume (PTV) consisted of the clinical target volume (CTV = obstructed bronchus or SVC) plus a 1 cm margin. For SMART, a dose of 10 Gy in a single treatment to the target was computed using 18 MV photons with 5 to 8 non-coplanar arcs with field sizes ranging from 4 cm2 to 8 cm2. For a dosimetric comparison using the same planning CT, an IMRT plan with 5 to 9 fields using 6 MV photons with 95% CTV coverage was computed to deliver the same dose. Dose volume histograms (DVH), treatment delivery time based on monitor units (MUs), and mean doses to the CTV, PTV, heart, lungs, spinal cord, and total body dose were compared using Student’s t-test. Results: Pooled DVH analysis of SMART and IMRT showed that SMART provided slightly better, but not statistically significant, coverage of the CTV (97±1.1 vs. 92±5%) and PTV (94±2 vs. 89±5%). There was no difference in normal tissue sparing between SMART and IMRT with respect to the mean lung dose (9±7 vs. 9±7%), heart dose (7±10 vs. 3±5%), cord dose (37±13 vs.30±13%), and total body dose (8±4 vs.7±4 Joules). However, SMART delivery was faster requiring significantly less MUs compared to IMRT (1,284±65 vs.1984±90, p<0.002). Conclusions: IMRT showed no advantage over SMART in dose coverage of the CTV/PTV and sparing of critical normal tissues. Therefore, less complex planning and faster treatment delivery of SMART maybe clinically preferable for rapid palliation of critically ill patients with an obstructed bronchus/SVC. No significant financial relationships to disclose.

scholarly journals Identification of lncRNAs associated with early stage breast cancer and their prognostic implications

2019 ◽  
Author(s):  
Arunagiri Kuha Deva Magendhra Rao ◽  
Krishna Patel ◽  
Sunitha Korivi Jyothi ◽  
Balaiah Meenakumari ◽  
Shirley Sundersingh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Rna Sequencing ◽  
Normal Tissue ◽  
Ductal Carcinoma ◽  
Early Stage ◽  
Expression Profiles ◽  
Prognostic Significance ◽  
Early Stage Breast Cancer ◽  
Paired Normal Tissue

AbstractBreast cancer is a common malignancy among women with the highest incidence rate worldwide. Dysregulation of long non-coding RNAs occurring in the preliminary stages of breast carcinogenesis is poorly understood. In this study, RNA sequencing was done to identify long non-coding RNA expression profiles associated with early-stage breast cancer. RNA sequencing was done in 6 invasive ductal carcinoma (IDC) tissues along with paired normal tissue samples, 7 ductal carcinomain situ(DCIS) tissues and 5 apparently normal breast tissues. We identified 375 differentially expressed lncRNAs (DElncRNAs) in IDC tissues compared to paired normal tissues. Antisense transcripts (∼58%) were the largest subtype among DElncRNAs. About 20% of the 375 DElncRNAs were supported by typical split readings leveraging their detection confidence. Validation was done in n=52 IDC and paired normal tissue by qRT-PCR for the identified targets (ADAMTS9-AS2, EPB41L4A-AS1, WDFY3-AS2, RP11-295M3.4, RP11-161M6.2, RP11-490M8.1, CTB-92J24.3 and FAM83H-AS)1. We evaluated the prognostic significance of DElncRNAs based on TCGA datasets and overexpression of FAM83H-AS1 was associated with patient poor survival. We confirmed that the down-regulation of ADAMTS9-AS2 in breast cancer was due to promoter hypermethylation through in-vitro silencing experiments and pyrosequencing.

Sign in / Sign up

Export Citation Format

Share Document